CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study
AB Gottlieb, TB Casale, E Frankel, B Goffe… - Journal of the American …, 2003 - Elsevier
BACKGROUND: Alefacept, human LFA-3/IgG1 fusion protein, selectively reduces memory-
effector (CD45RO+) T cells, a source of the pathogenic mediators of psoriasis. OBJECTIVE:
To evaluate the effect of alefacept on immune function, T-cell-dependent humoral responses
to a neoantigen (φX174) and recall antigen (tetanus toxoid) were assessed. METHODS:
Patients with psoriasis were randomized to the control group or to receive alefacept (7.5 mg
intravenously weekly for 12 weeks). The alefacept group received φX174 immunizations at …
effector (CD45RO+) T cells, a source of the pathogenic mediators of psoriasis. OBJECTIVE:
To evaluate the effect of alefacept on immune function, T-cell-dependent humoral responses
to a neoantigen (φX174) and recall antigen (tetanus toxoid) were assessed. METHODS:
Patients with psoriasis were randomized to the control group or to receive alefacept (7.5 mg
intravenously weekly for 12 weeks). The alefacept group received φX174 immunizations at …